Sixth Annual Targeted Therapies for the Treatment of Lung Cancer Conference

The CBCE
Ultima Vez Modificado: 18 de diciembre del 2005

Share article


English

Conference Dates: January 26, 2006
Conference Location: Santa Monica, CA

Sponsoring Group: The Center for Biomedical Continuing Education

Conference Web Page URL: www.thecbce.com/currentactivities.asp

Topics Covered: EGFR Inhibitors, Angiogenesis Inhibitors, Proapoptotic Agents, mTor/Map kinase/Signal Transduction/Akt, Novel Cytotoxics, Vaccines/Gene Therapy, Related Disease States and Radiation Therapy

Conference Objectives: After attending this activity, participants should be able to:

  1. Assess the efficacy of novel targeted-agent–based regimens currently under investigation for the treatment of your patients with lung cancer.
  2. Assess the results from recent studies aimed at identifying markers and patient characteristics predictive of response to specific therapeutic agents.
  3. Identify the critical factors for designing rational combinations with targeted agents for your patients with NSCLC .
  4. Describe the efficacy and safety of novel radiation techniques and regimens under investigation for the treatment of your patients with lung cancer.
  5. Based on the results of recent clinical trials, compare the risks and benefits of novel regimens for the second-line treatment of your patients with NSCLC.

Who Should Attend: The target audience will include medical and radiation oncologists, pathologists, community practitioners, researchers, fellows, and junior faculty involved in the diagnosis and management of patients with thoracic malignancies.

Registration Information: www.thecbce.com/currentactivities.asp

Conference Fees: Physician (in practice or academic research): $195. Fellow (with letter of fellow status from director): complimentary. Industry/All others: $1,895 (This category is defined by the CBCE as any person employed by a for-profit organization, including biotech, financial, and pharmaceutical.)

Continuing Education: Yes

English
News
AACR: Novel Breast Cancer Therapy Exploits Autophagy Response

Aug 1, 2014 - Targeting a cancer cell's heat shock response protein 70 with panobinostat to induce autophagy in the stressed cell, and then introducing an autophagy inhibitor to force the cell to die off, may be an effective novel treatment strategy for breast cancer, according to a Nov. 16 press briefing presented at the American Association for Cancer Research -- National Cancer Institute -- European Organisation for Research and Treatment of Cancer International Conference, "Molecular Targets and Cancer Therapeutics," held from Nov. 15 to 19 in Boston.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Frente a un nuevo diagnóstico de cáncer o de cambiar el curso de su tratamiento actual? Deje que nuestro personal de enfermería cáncer que ayudan a pasar!

Más información